tailieunhanh - Báo cáo khoa hoc:" N-acetylcysteine lacks universal inhibitory activity against influenza A viruses"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: N-acetylcysteine lacks universal inhibitory activity against influenza A viruses | Garigliany and Desmecht Journal of Negative Results in BioMedicine 2011 10 5 http content 10 1 5 r M 1 JOURNAL OF NEGATIVE RESULTS IN BIOMEDICINE BRIEF REPORT Open Access N-acetylcysteine lacks universal inhibitory activity against influenza A viruses Mutien-Marie O Garigliany and Daniel J Desmecht Abstract N-acetylcysteine NAC has been recently proposed as an adjuvant therapeutic drug for influenza pneumonia in humans. This proposal is based on its ability to restrict influenza virus replication in vitro and to attenuate the severity of the disease in mouse models. Although available studies were made with different viruses human and avian published information related to the anti-influenza spectrum of NAC is scarce. In this study we show that NAC is unable to alter the course of a fatal influenza pneumonia caused by inoculation of a murinized swine H1N1 influenza virus. NAC was indeed able to inhibit the swine virus in vitro but far less than reported for other strains. Therefore susceptibility of influenza viruses to NAC appears to be strain-dependent suggesting that it cannot be considered as a universal treatment for influenza pneumonia. Introduction About 10 percent of the human population is affected by influenza annually and several pandemic episodes have occurred throughout recorded history 1 . This context explains why continued efforts are made to identify new therapeutic molecules. Among these N-acetylcysteine NAC which is commonly used for its mucolytic activity in humans was shown to inhibit influenza virus both in mouse models alone or in combination with the A PR 8 strain 2 3 and in vitro with H5N1 strains 4 . Recently NAC treatment was reported to reduce symptoms of influenza-like illness in humans 5 and administration of the dose of 100 mg kg supposedly contributed to the success of the treatment of a patient infected with the 2009 pandemic H1N1 virus 6 . In order to determine whether these successful results can be extrapolated to .